High-Affinity CD16-polymorphism and Fc-Engineered Antibodies Enable Activity of CD16-chimeric Antigen Receptor-Modified T Cells for Cancer Therapy

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0341-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Development of Engineered T Cells Expressing a Chimeric CD16-CD3 Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2016English

Design and Implementation of Adoptive Therapy With Chimeric Antigen Receptor-Modified T Cells

Immunological Reviews
AllergyImmunology
2013English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed Against the AML Stem Cell Antigen CD96

PLoS ONE
Multidisciplinary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy